| CAS NO: | 320367-13-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Molecular Weight (MW) | 4858.49 |
|---|---|
| Formula | C215H347N61O65S |
| CAS No. | 320367-13-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: N/A |
| Water: 100 mg/mL (20.58 mM) | |
| Ethanol: N/A | |
| Sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2. |
| Synonyms | Lyxumia, Adlyxin, ZP10A peptide; ZP10 A peptide; ZP10-A peptide; AVE-0010; AVE0010; AVE 0010 |
| In Vitro | In vitro activity: Lixisenatide protects Ins-1 cells (a rat-derived β-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide also prevents lipotoxicity-induced insulin depletion in human islets and preserves insulin production, storage and pancreatic β-cell function in vitro. Binding studies in CHO-K1 cells overexpressing the human GLP-1 receptor show that Lixisenatide is a very potent and selective GLP-1 receptor agonist--the binding affinity of Lixisenatide (Ki = 1.33 ± 0.22 nM) is ~ 4-times greater than that of human GLP-1 (Ki = 5.09 ± 1.19 nM). In more than 80 different binding assays, lixisenatide does not exhibit any relevant interaction with other potential drug targets, confirming its high selectivity for the GLP-1 receptor Kinase Assay: Lixisenatide is a short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) with IC50 value of 1.4 nM for the human GLP-1 receptor in in vitro receptor binding studies. It can be administered through once-daily regimen. Cell Assay: Lixisenatide is able to protect Ins-1 cells (a rat-derived β-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide can also prevent lipotoxicity-induced insulin depletion in human islets and preserve insulin production, storage and pancreatic β-cell function in vitro. |
|---|---|
| In Vivo | The half-life of lixisenatide is 2-4 hours, and it is classed as a short-acting GLP-1-receptor agonist, compared with the long-acting GLP-1-based peptides, liraglutide and albiglutide. Lixisenatide can significantly improve glucose-stimulated insulin secretion. In healthy normoglycemic dogs, single subcutaneous injections of lixisenatide produces dose-dependent reductions in plasma glucose after an oral glucose challenge and significantly reduces postprandial glucose excursions by 67% compared with placebo without increasing insulin concentrations. The effect of lixisenatide on postprandial blood glucose excursions in dogs is, at least in part, related to inhibition of gastric emptying and delayed intestinal glucose absorption. Dose-dependent reductions in plasma glucose after an oral glucose challenge have also been demonstrated in both the db/db mouse and ZDF rat. Importantly, this activity is glucose-dependent with no effect at physiological glucose concentrations. In db/db mice, chronic lixisenatide administration preventes the progressive deterioration in glucose tolerance observed in control animals and is associated with significant dose-dependent reductions in glycosylated hemoglobin (HbA1c). In ZDF rats, a continuous subcutaneous infusion of lixisenatide 50 μg/kg/day for 12 weeks significantly decreases basal blood glucose and improves oral glucose tolerance compared with control animals. It has no hypoglycemic effect and does not change HbA1c in normoglycemic rats. Lixisenatide can maintain beta cell mass and function through stimulation of islet cell proliferation and neogenesis, and inhibition of islet cell apoptosis. |
| Animal model | Male db/db mice C57BLKS/J-Leprdb/Leprdb |
| Formulation & Dosage | phosphate-buffered saline, pH 7.4; 0.01, 0.1, 1, 10, and 100 nmol/kg; i.p. |
| References | Regul Pept. 2010 Sep 24;164(2-3):58-64; J Pharmacol Exp Ther. 2003 Nov;307(2):490-6; Core Evid. 2011;6:67-79. |
m.cnreagent.com